Thus, targeting MCL-1 represents a way to overcome the resistance of venetoclax refractory AML either through direct or indirect inhibitors (e.g., targeting MDM2, E3 ubiquitin-protein ligase) [72]. This evidence concerns the gene MDM2 and acute myeloid leukemia.